In This Article:
-
Revenue: $700.7 million, down 5% year-over-year on a GAAP basis; 3.8% decline on adjusted constant currency basis.
-
Adjusted Earnings Per Share (EPS): $2.91, a 9.3% decrease year-over-year.
-
Americas Revenue: $475.7 million, a 3.2% decrease year-over-year.
-
EMEA Revenue: $151.2 million, a 2.8% decrease year-over-year.
-
Asia Revenue: $73.8 million, a 9.7% decrease year-over-year.
-
Vascular Access Revenue: $182.4 million, a 1.9% increase year-over-year.
-
Interventional Revenue: $137.5 million, a 3.2% increase year-over-year.
-
Anesthesia Revenue: $86.6 million, an 8.6% decrease year-over-year.
-
Surgical Revenue: $105.8 million, a 2% increase year-over-year.
-
Interventional Urology Revenue: $71 million, a 10.7% decrease year-over-year.
-
OEM Revenue: $63.9 million, a 26.8% decrease year-over-year.
-
Other Revenue: $53.5 million, a 4.5% increase year-over-year.
-
Adjusted Gross Margin: 60.4%, a 70 basis point decrease year-over-year.
-
Adjusted Operating Margin: 24.7%, a 190 basis point decrease year-over-year.
-
Net Interest Expense: $16.6 million, down from $21 million in the prior year period.
-
Adjusted Tax Rate: 14.5%, up from 13.2% in the prior year period.
-
Cash Flow from Operations: $73.3 million, down from $112.8 million in the prior year period.
-
Cash and Cash Equivalents: $317.5 million at the end of the first quarter.
-
Net Leverage: Approximately 1.8x at quarter end.
-
Accelerated Share Repurchase Program: Completed with over 2.2 million shares repurchased at an average price of $135.23.
-
2025 Revenue Guidance: Adjusted constant currency growth of 1% to 2%; reported revenue growth of 1.3% to 2.3%.
-
2025 Adjusted EPS Guidance: $13.20 to $13.60.
Release Date: May 01, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Teleflex Inc (NYSE:TFX) reported first quarter revenues of $700.7 million, which was within the guidance range provided during the previous earnings call.
-
The Vascular Access segment saw a revenue increase of 1.9% year-over-year, driven by double-digit growth in PICCs and solid performance in EZ-IO.
-
The Interventional segment experienced a 3.2% year-over-year revenue increase, with strong demand for intra-aortic balloon pumps in the Americas.
-
The AC3 Range Intra-Aortic Balloon Pump received 510(k) clearance from the FDA, with full market release in the United States expected in the second quarter of 2025.
-
Teleflex Inc (NYSE:TFX) announced the intention to separate into two independent publicly traded companies, aiming to enhance shareholder value and strategic focus.